Skip to main content

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Recruiting · Phase 2, Phase 3 · NCT03435796

Conditions: Neoplasms

At a glance

Research payments reported, 2025
$1.1M
U.S. investigators named
67
Sites paid
68
Planned or actual enrollment
1,541

About the trial

Sponsor
Celgene
Tested
Gene-modified (GM) T cell therapy (genetic)
Dates
Started 2018-07-19; completion 2043-05-29
Results posted
Not yet

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Celgene Corporation reported $1.1M in research payments for this study in 2025 (88 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.